AstraZeneca Trial vs FDA Approval Timeline & Biomarker Impact Simulator

Broad Cohort Trial Status Trial Misses Primary Goal (9.4m vs 12.0m target) Observed median 9.4m PFS vs 12.0m target

Primary Endpoint Delta -2.6 Months Observed late-stage gap

Subgroup Responders 1.8x PFS improvement in biomarker-positive subset Biomarker-positive median PFS: 16.9m

Regulatory Divergence Approved for mutation-positive niche; missed broad endpoint Accelerated niche clearance vs failed ITT

Trial Parameters Interactive

Biomarker Mutation Population Target Mutation

FDA accelerated label was granted exclusively upon detection of the specific target mutation.

Target Biomarker Prevalence 18.5%

Share of advanced breast cancer cohort carrying specific target mutation.

Trial Endpoint Target PFS 12.0 mo

Prespecified primary progression-free survival (PFS) hurdle for broad indication.

Observed Broad Cohort PFS 9.4 mo

Actual reported late-stage median progression-free survival in broad study.

Progression-Free Survival (Kaplan-Meier Projection)

Comparing Biomarker Responders vs Intent-To-Treat (ITT) Broad Trial vs Control

Target Mutation Positive

Broad Cohort (Observed)

Pre-specified Target

Standard Care Control

Trial Population Segmentation

Prevalence sieve: Mutation positive vs Wild-type/Non-mutant

18.5% Mut+

81.5% Wild

Target Mutation: 18.5% (Approved indication) Wild-Type: 81.5% (Failed dilution)

Regulatory Timeline & Divergence

AstraZeneca Etcamah timeline chronology

WEEK -1

FDA Accelerated Approval Granted: Indicated strictly for advanced breast cancer patients harboring the specific target mutation.

WEEK 0

Late-Stage Trial Misses Primary Endpoint: Broad intent-to-treat cohort achieves only 9.4m PFS, falling 2.6m short of the 12.0m goal.

Clinical & Commercial Analysis (WSJ Report Grounding)

According to reporting by The Wall Street Journal, AstraZeneca’s breast cancer drug Etcamah encountered a stark regulatory dichotomy: just one week following accelerated U.S. FDA clearance for patients carrying a specific target mutation, the drug failed to hit its primary progression-free survival endpoint in a broader late-stage study. Because mutant carriers comprise only approximately 18.5% of the trial cohort, their pronounced therapeutic response (1.8x PFS improvement) was diluted by the wild-type non-responder majority, driving overall median PFS down to 9.4 months against the required 12.0 months.

Exportable Audit Record (JSON Blob Payload)

Source Attribution & Clinical Context

Source: The Wall Street Journal (@WSJ) report on AstraZeneca advanced breast cancer drug Etcamah late-stage trial goal miss post-accelerated FDA approval. Canonical post: WSJ Status 2099382892522524982. Simulated kinetics reflect standard parametric exponential survival models for oncology subgroup stratification.